Mediators of the resistance and aerobic exercise intervention effect on physical and general health in men undergoing androgen deprivation therapy for prostate cancer

- Buffart, Laurien M., Galvão, Daniel A., Chinapaw, Mai J., Brug, Johannes, Taaffe, Dennis R., Spry, Nigel, Joseph, David, Newton, Robert U.

Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial

- Capp, Anne, Inostroza-Ponta, Mario, Atkinson, Chris, North, John, Poulsen, Michael, Spry, Nigel A., Tai, Keen-Hun, Wynne, Chris, Duchesne, Gillian, Steigler, Allison, Denham, James W., Bill, Dana, Moscato, Pablo, Lai, Chi, Christie, David, Lamb, David, Turner, Sandra, Joseph, David, Matthews, John

Improving sexual health in men with prostate cancer: randomised controlled trial of exercise and psychosexual therapies

- Cormie, Prue, Chambers, Suzanne K., Hamilton, Kyra, Galvão, Daniel A., Newton, Robert U., Gardiner, Robert A., Spry, Nigel, Taaffe, Dennis R., Joseph, David, Hamid, M. Akhlil, Chong, Peter, Hughes, David

Functional benefits are sustained after a program of supervised resistance exercise in cancer patients with bone metastases: longitudinal results of a pilot study

- Cormie, Prue, Galvão, Daniel A., Spry, Nigel, Joseph, David, Taaffe, Dennis R., Newton, Robert U.

Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial

- Cormie, Prue, Galvão, Daniel A., Spry, Nigel, Joseph, David, Chee, Raphael, Taaffe, Dennis R., Chambers, Suzanne K., Newton, Robert U.

Gleason scoring: a comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point

- Delahunt, Brett, Lamb, David S,, Srigley, John R., Murray, Judy D,, Wilcox, Chantelle, Samaratunga, Hemamali, Atkinson, Christopher, Spry, Nigel A., Joseph, David, Denham, James W.

Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial

- Delahunt, Brett, Murray, Judith D., Samaratunga, Hemamali, Spry, Nigel A., Srigley, John R., Hondermarck, Hubert, Denham, James W., Steigler, Allison, Atkinson, Chris, Christie, David, Duchesne, Gillian, Egevad, Lars, Joseph, David, Matthews, John, Oldmeadow, Christopher

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Wynne, Chris, D'Este, Catherine, Lamb, David S., Joseph, David, Turner, Sandra, Matthews, John, Atkinson, Chris, North, John, Christie, David, Spry, Nigel A.

Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?

- Denham, James W., Steigler, Allison, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Tai, Keen-Hun, Spry, Nigel A., Gleeson, Paul S., D'Este, Catherine

PSA response signatures: a powerful new prognostic indicator after radiation for prostate cancer?

- Denham, James W., Lamb, David S., Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Duchesne, Gillian, Ebert, Martin, Steigler, Allison, D'Este, Catherine

Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer

- Denham, James W., Wilcox, Chantelle, Gogna, Nirdosh Kumar, Ebert, Martin, Delahunt, Brett, McElduff, Patrick, Joseph, David, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Atkinson, Chris, Matthews, John, Turner, Sandra, Kenny, Lizabeth, Tai, Keen-Hun

Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer

- Denham, James W., Steigler, Allison, Wynne, Chris, Lamb, David S., Tai, Keen-Hun, Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Turner, Sandra, North, John, Christie, David

Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer

- Denham, James W., Kumar, Mahesh, Turner, Sandra, Greer, Peter B., D'Este, Catherine, Steigler, Allison, Gleeson, Paul S., Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

- Denham, James W., Steigler, Allison, Gleeson, Paul S., Greer, Peter B., D'Este, Catherine, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial

- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Gogna, Nirdosh Kumar, Gill, Suki, Tan, Hendrick, Kearvell, Rachel, Murray, Judy, Ebert, Martin, Haworth, Annette, Kennedy, Angel, Delahunt, Brett, Joseph, David, Oldmeadow, Christopher, Holliday, Elizabeth G., Attia, John, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Atkinson, Chris, Matthews, John, Turner, Sandra, Kenny, Lizbeth

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial

- Denham, James W., Wilcox, Chantelle, Gogna, Nirdosh Kumar, Kenny, Lizbeth, Duchesne, Gillian, Delahunt, Brett, McElduff, Patrick, Joseph, David, Spry, Nigel A., Lamb, David S., Tai, Keen-Hun, Matthews, John, Atkinson, Chris, Turner, Sandra, Christie, David

Measuring time to biochemical failure in the Trog 96.01 trial: when should the clock start ticking?

- Denham, James W., Steigler, Allison, Gleeson, Paul S., D'Este, Catherine, Kumar, Mahesh, Lamb, David S., Joseph, David, Spry, Nigel A., Tai, Keen-Hun, Atkinson, Chris, Turner, Sandra, Greer, Peter B.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

- Denham, James W., Joseph, David, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Matthews, John, Atkinson, Chris, Tai, Keen-Hun, Christie, David, Kenny, Lizbeth, Turner, Sandra, Gogna, Nirdosh Kumar, Diamond, Terry, Delahunt, Brett, Oldmeadow, Chris, Attia, John, Steigler, Allison

Cost-effectiveness analysis of supervised exercise training in men with prostate cancer previously treated with radiation therapy and androgen-deprivation therapy

- Edmunds, Kim, Reeves, Penny, Tuffaha, Haitham, Scuffham, Paul, Galvão, Daniel A., Newton, Robert U., Jones, Mark, Spry, Nigel, Taaffe, Dennis R., Joseph, David, Chambers, Suzanne K.

Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response

- Galvao, Daniel A., Taaffe, Dennis R., Spry, Nigel, Joseph, David, Newton, Robert U.